October 2026—In the never-ending search for new cancer biomarkers, there is always at least one new hopeful waiting in the wings, readying for a potential elevation (so to speak) to star status. Among the latest to generate buzz (at least in the form of oncologists asking about testing) are MTAP deletions. Could these be the latest to have a breakout role? There are many good reasons to think so, says Eric Vail, MD.
October 2026—Antibiotic resistance has changed dramatically. How laboratories detect antibiotic resistant infections and how patients are treated have not. “We treat patients with our best-guess drugs, and we make those guesses based on the types of infections we’re seeing in the patients we take care of and what our local antibiotic resistance rates look like,” says Romney Humphries, PhD, D(ABMM), M(ASCP).
October 2026—This conversation is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with representatives of a company to spotlight its laboratory solutions. He spoke on July 21 with Nick Fingland, PhD, PMP, senior director of R&D operations and science, BD, and Chris Farnsworth, PhD, D(ABCC), section head of clinical chemistry, WashU Medicine, and professor of pathology and immunology and of emergency medicine, Washington University. McGonnagle’s questions and their answers follow. The title of their talk: Where quality begins: the real impact of blood collection choices.
Watch the full conversation:
This roundtable discussion is sponsored by BD.
October 2026—We have all heard the latest claims that the American Medical Association—and the medical specialties it represents—is misusing CPT codes to overpay physicians. Whether these statements come from the Medicare Payment Advisory Commission, members of Congress, or any other group, it’s no wonder we pathologists feel under attack.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: Hematology Analyzers
October 2026—Differential reviews, reference ranges, longitudinal data, AI, and information silos were front and center when CAP TODAY publisher Bob McGonnagle led a discussion online in early September about hematology analyzers and the needs of laboratories and clinicians.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
December 2020—Protein-based, ready-to-use liquid Matrix Plus Cholesterol Reference kits are available from Verichem Laboratories. The kits are designed to support overall system quality control and CLIA compliance and are for the calibration or calibration verification of cholesterol and uric acid wet assays on clinical testing systems. The materials contain esterified and free cholesterol from bovine serum. The standard kit with the sixth level F covers 12 concentration points; cholesterol concentrations range from 40 to 750 mg/dL and uric acid concentrations from 2 to 30 mg/dL. Active components are verified using standard reference materials from the National Institute of Standards and Technology. Shelf life is 21 months from the date of manufacture. Ready-to-use, liquid Total Protein and Albumin reference materials are also available. The combined Total Protein/Albumin Standard kit, along with the optional standalone Total Protein/Albumin Standard level F, are designed for the calibration and calibration verification of albumin and total protein assays on a wide number of clinical testing systems. The standards are prepared with human serum albumin and gamma-globulin serum proteins in a saline-based solution. Shelf life is 24 months from the manufacturing date.